Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 15/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5942308 | 0.92 | CHRM5 (0.42) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5941620 | 0.85 | MKNK1 (0.41) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5274358 | 0.84 | NR1H2 (0.45) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5941924 | 0.84 | MKNK1 (0.40) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3085985 | 0.82 | CHRM5 (0.41) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5272921 | 0.81 | CHRM5 (0.39) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9350724 | 0.80 | GPR119 (0.47) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3197517 | 0.79 | SLC6A3 (0.54) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL6418231 | 0.79 | CHRM5 (0.59) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL5942384 | 0.79 | CHRM5 (0.40) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004105738-A2 | USE OF TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | CHRM5 1155/4885CHRM1 1851/4885CHRM2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.